Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0013841017
Thu, 20.04.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Increases Straight Bond by CHF 150 Million
20.04.2023 / 18:30 CET/CEST
Basel, Switzerland, 20 April 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the increase of the Straight Bond issued on 8 February 2023 by CHF 150 m [ … ]
Fri, 31.03.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Corporate Action
Lonza Launches Share Buyback Program of up to CHF 2 Billion
31.03.2023 / 07:00 CET/CEST
Basel, Switzerland, 31 March 2023 – On 3 April 2023, Lonza will launch a share buyback program of up to CHF 2 billion, as announced on 25 January 2023. Enabled by Lonza’s strong balance sheet and [ … ]
Fri, 31.03.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Corporate Action
Lonza Launches Share Buyback Program of up to CHF 2 Billion
31.03.2023 / 07:00 CET/CEST
Basel, Switzerland, 31 March 2023 – On 3 April 2023, Lonza will launch a share buyback program of up to CHF 2 billion, as announced on 25 January 2023. Enabled by Lonza’s strong balance sheet and [ … ]
Wed, 29.03.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Expansion
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
29.03.2023 / 09:00 CET/CEST
Lonza increases capacity and capabilities in Visp (CH) with the completion of a new line for cGMP clinical and commercial drug product manufacturing
The line is fully operati [ … ]
Wed, 29.03.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Expansion
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
29.03.2023 / 09:00 CET/CEST
Lonza increases capacity and capabilities in Visp (CH) with the completion of a new line for cGMP clinical and commercial drug product manufacturing
The line is fully operati [ … ]
Mon, 27.03.2023
Lonza Group AG
Ad hoc announcement pursuant to Art. 53 LR
Annual General Meeting to take place on 5 May 2023 at the Congress Center in Basel, Switzerland
Albert M. Baehny proposed for re-election as Chairman of the Board of Directors, all current Board Members proposed for re-election
KPMG proposed for re-election as auditors for the financial year 2023, with Del [ … ]
Mon, 27.03.2023
Lonza Group AG
Ad hoc announcement pursuant to Art. 53 LR
Annual General Meeting to take place on 5 May 2023 at the Congress Center in Basel, Switzerland
Albert M. Baehny proposed for re-election as Chairman of the Board of Directors, all current Board Members proposed for re-election
KPMG proposed for re-election as auditors for the financial year 2023, with Del [ … ]
Thu, 16.02.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Expansion
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
16.02.2023 / 14:00 CET/CEST
Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates
The Visp (CH) investment includes two manufacturin [ … ]
Thu, 16.02.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Expansion
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
16.02.2023 / 14:00 CET/CEST
Expansion adds development and manufacturing capacity for pre-clinical, clinical and commercial supply of bioconjugates and antibody-drug conjugates
The Visp (CH) investment includes two manufacturin [ … ]
Wed, 08.02.2023
Lonza Group AG
Lonza Group AG
/ Key word(s): Bond/Financing
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
08.02.2023 / 18:30 CET/CEST
Basel, Switzerland, 08 February 2023 – Lonza Swiss Finance Ltd, a wholly owned company of Lonza Group Ltd, Basel (“Lonza”), announced today the pricing of a CHF 300 million straight-bond issu [ … ]